journal
MENU ▼
Read by QxMD icon Read
search

Clinical Advances in Hematology & Oncology: H&O

journal
https://www.readbyqxmd.com/read/28398276/bcl-2-as-a-therapeutic-target-in-chronic-lymphocytic-leukemia
#1
REVIEW
Catherine Daniel, Anthony R Mato
Venetoclax (formerly ABT-199) was recently approved in the United States for the treatment of patients who have relapsed or refractory chronic lymphocytic leukemia (CLL) with the 17p deletion. Venetoclax has demonstrated marked activity as monotherapy as well as in combination with cytotoxic chemotherapies, B-cell receptor inhibitors, and anti-CD20 monoclonal antibodies across the spectrum of CLL. The potency of venetoclax has been associated with a unique ability to induce deep (minimal residual disease-negative) complete remissions that appear to be durable...
March 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398275/natural-killer-t-cell-lymphomas-in-pediatric-and-adolescent-patients
#2
REVIEW
Amanda M Termuhlen
Natural killer/T-cell (NK/T-cell) lymphomas are rare in children and adolescents and consist predominantly of nasal-type extranodal NK/T-cell lymphomas. More than half of pediatric/adolescent patients with NK/T-cell lymphomas present with localized nasal/sinus involvement, but the disease may involve many organs. NK/T-cell lymphoma cells are cytotoxic and associated with necrosis and angioinvasion; they express CD56, CD2, cytoplasmic CD3 epsilon, and to a variable degree CD30. The cells contain Epstein-Barr virus (EBV)-encoded RNA...
March 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398274/the-new-nccn-guidelines-for-the-management-of-myelofibrosis
#3
Ruben A Mesa
No abstract text is available yet for this article.
March 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398273/the-use-of-immunotherapy-in-the-first-line-treatment-of-lung-cancer
#4
Naiyer A Rizvi
No abstract text is available yet for this article.
March 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398272/prognostic-and-predictive-biomarkers-in-metastatic-castration-resistant-prostate-cancer
#5
Andrew J Armstrong
No abstract text is available yet for this article.
March 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398271/prevention-and-management-of-thrombosis-in-myeloproliferative-neoplasms
#6
Mallika Sekhar
No abstract text is available yet for this article.
March 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398270/the-evolving-role-of-cyclin-dependent-kinase-inhibitors-in-cancer-management
#7
Geoffrey I Shapiro
No abstract text is available yet for this article.
March 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398269/letter-from-the-editor-when-will-we-beat-r-chop
#8
Brad S Kahl
No abstract text is available yet for this article.
March 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398285/evolving-standards-of-care-for-resected-pancreatic-cancer
#9
REVIEW
Benjamin A Weinberg, Philip A Philip, Mohamed E Salem
Pancreatic cancer is a devastating illness, and surgical resection offers the only chance of a cure for patients with the disease. Relatively few patients have resectable disease at diagnosis, however, and the cancer frequently recurs even after complete surgical resection. This review discusses clinical trials in which adjuvant therapy with chemotherapy or chemoradiation has prolonged survival in patients following surgery. It also highlights new data from the ESPAC-4 and JASPAC 01 studies that may change the current treatment paradigm for adjuvant therapy...
February 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398284/manifestations-and-management-of-veno-occlusive-disease-sinusoidal-obstruction-syndrome-in-the-era-of-contemporary-therapies
#10
REVIEW
Priti Tewari, Whitney Wallis, Partow Kebriaei
The concept of veno-occlusive disease (VOD), along with our understanding of it, has historically been and remains an evolving phenomenon. This review presents a broad view of VOD, also known as sinusoidal obstruction syndrome (SOS), including (1) traditional hematopoietic stem cell transplant-associated VOD/SOS, (2) late-onset VOD/SOS, (3) pulmonary VOD, and (4) VOD/SOS associated with chemotherapy only. Several VOD/SOS management modalities exist that include modes for both prophylaxis and treatment. An extensive review of the literature on monoclonal antibodies, both approved and pending approval by the US Food and Drug Administration, reveals that only a few have been associated with an increased risk for VOD/SOS...
February 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398283/the-future-of-immunotherapy-as-perioperative-therapy-in-renal-cell-carcinoma
#11
(no author information available yet)
No abstract text is available yet for this article.
February 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398282/the-role-of-regorafenib-in-hepatocellular-carcinoma
#12
Catherine T Frenette
No abstract text is available yet for this article.
February 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398281/an-interim-analysis-of-the-zuma-1-study-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma
#13
Sattva S Neelapu
No abstract text is available yet for this article.
February 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398280/highlights-in-gene-therapy-and-alternative-therapies-in-nonmalignant-hematology-from-the-2016-american-society-of-hematology-meeting
#14
(no author information available yet)
No abstract text is available yet for this article.
February 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398279/is-there-a-role-for-single-agent-braf-inhibition-in-melanoma
#15
Bartosz Chmielowski
No abstract text is available yet for this article.
February 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398278/barriers-to-the-development-of-drugs-for-primary-brain-tumors
#16
Susan M Chang
No abstract text is available yet for this article.
February 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28398277/letter-from-the-editor-inauguration-week
#17
Brad S Kahl
No abstract text is available yet for this article.
February 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28212372/molecular-biology-of-gastroesophageal-cancers-opportunities-and-challenges
#18
REVIEW
Shaheer Khan, Sameh Mikhail, Joanne Xiu, Mohamed E Salem
Gastroesophageal (GE) malignancies make up a significant and growing segment of newly diagnosed cancers. Approximately 80% of patients who have GE cancers die within 5 years of diagnosis, which means that effective treatments for these malignancies need to be found. Currently, targeted therapies have a minimal role in this disease group. Intensive study of the molecular biology of GE cancers is a relatively new and ongoing venture, but it has already led to a significant increase in our understanding of these malignancies...
January 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28212371/circulating-tumor-cells-in-prostate-cancer-beyond-enumeration
#19
Jie-Fu Chen, Yi-Tsung Lu, Shirley Cheng, Hsian-Rong Tseng, Robert A Figlin, Edwin M Posadas
Circulating tumor cells (CTCs) are a population of rare cancer cells that have detached from the primary tumor and/or metastatic lesions and entered the peripheral circulation. Enumeration of CTCs has demonstrated value as a prognostic biomarker, and newer studies have pointed to information beyond enumeration that is of critical importance in prostate cancer. Technologic advances that permit examination of the morphology, function, and molecular content of CTCs have made it possible to measure these factors as part of liquid biopsy...
January 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28212370/the-evolution-of-allogeneic-stem-cell-transplant-for-children-and-adolescents-with-acute-myeloid-leukemia
#20
Allyson Flower, Mitchell S Cairo
Survival rates in subsets of pediatric patients who have acute myeloid leukemia (AML) with favorable risk features are now greater than 90%. However, outcomes for patients with high-risk (HR) features remain unacceptably poor. As novel technologies for the identification of HR biomarkers and the detection of residual disease are developed, risk stratification and the application of allogeneic hematopoietic stem cell transplant (HSCT) are evolving. HSCT has been shown to benefit subpopulations of pediatric patients with AML, including those with HR cytogenetic translocations, genetic mutations, and/or residual disease after induction...
January 2017: Clinical Advances in Hematology & Oncology: H&O
journal
journal
40386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"